Morning sickness drugs may not be as efficient as they were thought to be. Specialists believe that pregnant women who usually take a pill to diminish the symptoms of morning sickness should think twice before doing it. The drug is called Diclegis. Back in 2015, Kim Kardashian talked about this drug when she was pregnant with Saint. When is posted about the pill, she never mentioned the side effects which may appear.
Experts argued that the efficiency of this drug is currently being questioned. No one should truly trust such pills. Apparently, in the last forty years, many women around the global used Diclegis to treat their morning sickness because the tablet contained doxylamine and pyridoxine. These represent two essential ingredients which managed to ease the burden with which every woman was confronting during pregnancy.
There were several obstetricians and health agencies which recommended the drug. Thus, approximately 35 million women consumed it. Nevertheless, a new study proves that the effects of this pill might not have been so efficient. The new research was published on January 4 in PLOS One by researchers from Toronto. They have closely analyzed the effects of this medicine.
The data presented was gathered from a clinical trial which was conducted back in the 1970s. That survey was examined until recently because it represented a significant factor in the approval of the drug. The lead author of this new analysis is Nav Persaud, a researcher, and physician at St. Michael’s Hospital in Canada. He became interested in this pill when a patient of his asked him if the morning sickness drug is recommended.
After the pregnant lady had left, he started searching for more data concerning this treatment. At first, he even had problems finding basic information about the pill in question. He needed many years to carefully study the medicine to realize that there is no reason for which doctors should recommend this tablet to others.
The new study which was conducted by Merrell-National Laboratories had analyzed about 2,308 patients who pertained to 14 clinics in the US. The studies only examined the effects of this pill in the first three months of pregnancy of women who complained about the consequences of this drug. Unfortunately, the study never got to a conclusion. Thus, Persaud asked the FDA to take responsibility for issuing guidelines to do reviews on this pill.
Image source: pixabay